News
VSTM
13.09
+3.07%
0.39
Weekly Report: what happened at VSTM last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at VSTM last week (0212-0216)?
Weekly Report · 02/19 12:05
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Big Lots, Inc. Shares dipped 31.3% to $3.6850 on Monday. The company reported preliminary fourth-quarter results. Millennium Group International Holdings Limited (NASDAQ:MGIH) shares surged 250% in the mid-day session. Big Lots shares fell sharply after Loop Capital downgraded the stock from Hold to Sell.
Benzinga · 02/12 18:07
Weekly Report: what happened at VSTM last week (0205-0209)?
Weekly Report · 02/12 11:52
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
NASDAQ · 02/07 12:15
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib
Seeking Alpha · 02/07 06:01
Weekly Report: what happened at VSTM last week (0129-0202)?
Weekly Report · 02/05 12:03
Verastem Outlines Strategic Priorities for 2024
TipRanks · 01/30 09:40
Buy Rating on Verastem: Strategic Execution and Promising Drug Pipeline Signal Market Opportunity
TipRanks · 01/30 01:46
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
Benzinga · 01/29 12:04
Weekly Report: what happened at VSTM last week (0122-0126)?
Weekly Report · 01/29 11:48
Verastem: Statement of changes in beneficial ownership of securities
Press release · 01/25 12:04
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
NASDAQ · 01/22 13:15
Weekly Report: what happened at VSTM last week (0115-0119)?
Weekly Report · 01/22 11:54
Verastem Shareholders Approve Executive Option Exchange Plan
Verastem, Inc. Held a Special Meeting in Needham, Massachusetts, on January 17, 2024. The stockholders approved a proposal to allow a one-time option exchange for certain executives, employees and non-employee directors. The company's stock is up 1.7% to $3.50.
TipRanks · 01/20 08:06
Verastem: Current report
Press release · 01/19 16:02
Health Care Sector Update for 01/19/2024: VSTM, CHRS, AEON, XLV, IBB
NASDAQ · 01/19 14:14
Verastem : Avutometinib Combination Receives Fast Track Designation For KRAS G12C-Mutant NSCLC
NASDAQ · 01/19 03:45
Verastem gets FDA fast track status for lung cancer drug combo
Healthcare Verastem gets FDA fast track status for lung cancer drug combo. The designation is for avutomentinib in combination with Amgen’s Lumakras for the treatment of certain type of lung cancer.  Verastem Oncology said it has received FDA fast-track status for its drug candidate avutometinib.
Seeking Alpha · 01/18 21:28
More
Webull provides a variety of real-time VSTM stock news. You can receive the latest news about Verastem through multiple platforms. This information may help you make smarter investment decisions.
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company’s pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, Avutometinib (VS-6766) and Defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and melanoma. VS-6766 is an orally available small molecule RAF/MEK clamp. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.